Formycon Launches Aflibercept Biosimilars in EU

Formycon AG, in collaboration with Klinge Biopharma GmbH, has launched the biosimilars Ahzantive® and Baiama® in the European Union. These prefilled syringes of FYB203, an aflibercept biosimilar, are now available in key EU markets like Germany, France, and Italy. The rollout is part of Formycon's FYB4Growth strategy, which aims to broaden its market presence through partnerships.

Nicola Mikulcik, Formycon's CBO, highlighted the significance of this launch in scaling their portfolio, offering cost-effective treatment options for severe retinal diseases. The biosimilars were introduced following a settlement with Regeneron and Bayer, aligning with their planned U.S. launch in late 2026.

These biosimilars cater to the treatment of neovascular age-related macular degeneration, providing a crucial option for patient care across European markets.